Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy
Authors:
Open Access
- 25 August 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 15 (1) , 79-85
Abstract
Aspartylglycosaminuria (AGU) is caused by deficient enzymatic activity of glycosylasparaginase (GA). The disease is characterized by accumulation of aspartylglucosamine (GlcNAc-Asn) and other glycoasparagines in tissues and body fluids of AGU patients and in an AGU mouse model. In the current study, we characterized a glycoasparagine carrying the tetrasaccharide moiety of α-D-Man-(1→6)-β-D-Man-(1→4)-β-D-GlcNAc-(1→4)-β-D-GlcNAc-(1→N)-Asn (Man2GlcNAc2-Asn) in urine of an AGU patient and also in the tissues of the AGU mouse model. Quantitative analysis demonstrated a massive accumulation of the compound especially in nonneuronal tissues of the AGU mice, in which the levels of Man2GlcNAc2-Asn were typically 30–87% of those of GlcNAc-Asn. The highest level of Man2GlcNAc2-Asn was found in the liver, spleen, and heart tissues of the AGU mice, the respective amounts being 87%, 76%, and 57% of the GlcNAc-Asn levels. In the brain tissue of AGU mice the Man2GlcNAc2-Asn storage was only 9% of that of GlcNAc-Asn. In contrast to GlcNAc-Asn, the storage of Man2GlcNAc2-Asn markedly increased in the liver and spleen tissues of AGU mice as they grew older. Enzyme replacement therapy with glycosylasparaginase for 3.5 weeks reduced the amount of Man2GlcNAc2-Asn by 66–97% in nonneuronal tissues, but only by 13% in the brain tissue of the AGU mice. In conclusion, there is evidence for a role for storage of glycoasparagines other than aspartylglucosamine in the pathogenesis of AGU, and this possibility should be taken into consideration in the treatment of the disease.Keywords
This publication has 20 references indexed in Scilit:
- Rapid Clearance of Sialylated Glycoproteins by the Asialoglycoprotein ReceptorJournal of Biological Chemistry, 2003
- A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome)Glycobiology, 1999
- Progressive Neurodegeneration in Aspartylglycosaminuria MiceThe American Journal of Pathology, 1998
- A mouse model for the human lysosomal disease aspartylglycosaminuriaNature Medicine, 1996
- Assay of aspartylglycosylaminase by high-performance liquid chromatographyAnalytical Biochemistry, 1990
- Analysis of aspartylglucosamine at the picomole level by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1989
- Selective determination of secondary amino acids using precolumn derivatization with 9-fluorenylmethylchloroformate and reversed-phase high-performance liquid chromatographyJournal of Chromatography A, 1985
- Quantitative analysis, by gas-liquid chromatography and mass fragmentography, of monosaccharides after methanolysis and deaminationCarbohydrate Research, 1981
- Accumulation of two glycoasparagines in the liver in aspartylglycosaminuria.Journal of Biological Chemistry, 1979
- Enzymatic cleavage of glycopeptidesBiochemical and Biophysical Research Communications, 1966